Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

Shares of Viking Therapeutics Inc. have dropped over 40% in the last six months, leading to a significant decline in retail ...

Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

The server maker, shares of which were the most volatile in the S&P 500 last year, has yet to make public its earnings for ...

Investors could be encouraged by news from TSMC, which reported a surge in profit on strong demand for AI semiconductors.